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Layering a regenerative polymer scaffold on the surface of the heart, termed as a cardiac patch, has been proven to
be effective in preserving cardiac function after myocardial infarction (MI). However, the placement of such a
patch on the heart usually needs open-chest surgery, which is traumatic, therefore prevents the translation of this
strategy into the clinic. We sought to device a way to apply a cardiac patch by spray painting in situ polymerizable
biomaterials onto the heart with a minimally invasive procedure. To prove the concept, we used platelet fibrin gel
as the ‘‘paint’’ material in a mouse model of MI. The use of the spraying system allowed for placement of a
uniform cardiac patch on the heart in a mini-invasive manner without the need for sutures or glue. The spray
treatment promoted cardiac repair and attenuated cardiac dysfunction after MI.
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Introduction
Myocardial infarction (MI) is a major cause of deathworldwide.1 It results in cardiomyocyte loss, myocar-
dial remodeling, and the deterioration of cardiac function,
which can eventually lead to heart failure.2 Current therapies,
including conventional pharmacological agents and left ven-
tricular (LV) assist devices can only delay the progression of
the disease, and the shortage of heart donors is also a factor for
innovating new therapies.3 Therefore, new therapies are nee-
ded to regenerate damaged hearts to overcome the poor
prognosis of patients with heart failure.
The emergence of biomaterials and cardiac tissue engi-
neering has started to provide promising alternatives. Over the
last 5 years, the general biomaterial approaches to treatment of
MI have remained the same: LV restraints, cardiac patches,
or injectable hydrogel biomaterials.4 Layering a regenera-
tive polymer scaffold on the surface of the heart, termed as a
cardiac patch, has been proven to be effective in preserving
cardiac function after MI.5 However, the placement of such
a patch on the heart usually needs open-chest surgery, which
is traumatic, therefore prevents the translation of this tech-
nology to the clinic. We sought to device a way to apply a
cardiac patch onto the heart in a minimally invasive way.
Inspired by the practice of spray painting used by con-
struction industry, we hypothesize that in situ polymerizable
biomaterials can be spray painted onto the surface of the
heart to form a uniform layer of cardiac patch. To prove the
concept, we used platelet fibrin gel as the ‘‘paint’’ material
and used a biomaterials spray device in a mouse model of
MI. Platelet fibrin gel is known for its ability to quickly aid
in clot formation and has been used a biomaterial for cardiac
repair in animal studies.3,4,6
Materials and Methods
Ethics statement
This study was carried out in strict accordance with
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protocol was approved by Institutional Animal Care and
Usage Committee at North Carolina State University. All
surgeries were performed under isofluorane combined with
oxygen, and all efforts were made to minimize suffering.
Animals were euthanized through inhalation of CO2.
Preparation of platelet fibrin gel spray
A uniform platelet fibrin patch was formed by spraying
platelet-rich plasma and calcium-containing media solution
(through a double-lumen syringe, with the aid from com-
pressed CO2. Platelet-rich plasma was derived from CD1
mice as previously described.7 The solutions were delivered
through the home-designed spray set, which hold the two
components in separate 1mL syringes and provided simul-
taneous mixing and delivery. The ratio of platelet-rich
plasma to calcium-containing media solution components
was 1:1 as previously described.7 A tube carried compressed
CO2 air of 10 PSI pressure to the syringe tip to create the
spray of the two components onto the heart or onto in vitro
cultured cells.
Characterization of the sprayed platelet fibrin patch
To determine the gelation time of platelet fibrin gel, we
monitored gel formation over time by spraying platelet fibrin
gel onto coverslips. A stress-controlled shear rheometer (AR-
2000; TA Instruments) with 20mm parallel disc geometry was
used to evaluate the rheological properties of the gelation
process.Tovisualize themorphological details of platelet fibrin
FIG. 1. Overall study design. (A) Schematic showing the spray painting of biomaterials on the heart after myocardial
infarction. (B, C) Design of a spray painting device for regenerative biomaterials.
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gel, fresh platelet fibrin gel samples were prepared and fixed
with 2%glutaraldehyde in 0.1M sodiumcacodylate buffer (pH
7.2) for 1 h and then rinsed with cacodylate buffer three times
(15min each).The sampleswere thendehydrated in35%,50%,
70%, 80%, 95%, and 100% ethanol successively for 10min
each and dried in hexamethyldisilazane (Sigma Aldrich, MO).
Scaffolds were sputter-coated with gold, and images were
captured with a JEOL JSM-6380 LV (JEOL Ltd, Japan). To
study whether this kind of platelet fibrin gel could release
vascular endothelial growth factor (VEGF), insulin-likegrowth
factor (IGF)-1, hepatocyte growth factor (HGF), platelet-
derived growth factor (PDGF), and transforming growth
factor-beta (TGF-b), we collected conditioned media at day 2,
5, 9, and 14, and fresh media were added back into the culture
plate well to be conditioned for next time points. Enzyme-
linked immunosorbent assay kits were used to determine the
expression of VEGF, IGF-1, HGF, PDGF, and TGF-b.
Cardiomyocyte biocompatibility with the sprayed
platelet fibrin patch
To determine the biocompatibility of platelet fibrin patch
to cardiomyocytes, we cultured fresh neonatal rat cardio-
myocytes (NRCMs) from Sprague–Dawley (SD) rats. The
NRCMs harvesting and culturing methods were entailed in
previous studies.8,9 To distinguish if the mechanical force
from spray operation has impact on cardiomyocytes, we
cultured NRCMs on presprayed gel (NRCM on Spray) or
sprayed gel directly onto preplated NRCMs (Spray on
NRCM). We also cultured NRCMs on standard tissue cul-
ture plate (TCP) coated with fibronectin (BD Bioscience,
CA) as the control. The percentage of viable NRCMs was
determined by the LIVE/DEAD Viability/Cytotoxicity Kit
(Invitrogen, CA), which quickly discriminates live from
dead cells by simultaneously staining with green-fluorescent
FIG. 2. Characterization of the sprayed platelet fibrin patch in vitro. (A) Mixing platelet-rich plasma with calcium-
containing media solution in compressed air by the spray set resulted in a stable gel formation in less than 1min; (B)
Hematoxylin–eosin staining revealed a fibrous structure of the sprayed platelet fibrin gel; (C) Representative scanning
electron microscopy images of the sprayed platelet fibrin gel; (D–H) Enzyme-linked immunosorbent assay (ELISA) of the
concentrations of vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF)-1, hepatocyte growth factor
(HGF), platelet-derived growth factor (PDGF), and transforming growth factor-beta (TGF-b) from sprayed platelet fibrin
gel conditioned media at different time points (n = 3 per time points). Scale bar= 100 mm. H & E, hematoxylin and eosin.
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calcein-AM (live) and red-fluorescent ethidium homodimer-
1 (EthD; dead). Cell morphology was characterized from the
same images using the ImagePro software (Media Cyber-
netics, MD). Videos capturing cardiomyocyte contraction
were taken at day 1 and 7.
Animal studies
The method to induce MI in mice was based on previous
study.10 In brief, male CD1 mice were anesthetized with 3%
isoflurane combined with oxygen inhalation. Under sterile
conditions, the heart was exposed by a minimally invasive
left thoracotomy, and acute MI was produced by permanent
ligation of the left anterior descending coronary artery with
metal clip dispensed by AutoSuture Surgiclip (Autosuture).
Immediately after MI induction, the mice received one of
the following four treatments: (1) MI+ Platelet Fibrin Spray
group: Spray of 200 mL platelet fibrin gel onto the heart
immediately after MI; (2) MI+ Fibrin Spray group: Spray of
200 mL fibrin gel onto the heart immediately after MI; (3)
MI alone group: MI surgery without spray; and (4) SHAM
group: thoracotomy only without AMI. After chest closure,
animals were transferred to the care unit for recovery and
received carprofen (5mg/kg) once daily and buprenorphine
(0.05mg/kg) twice daily for up to 48 h. All animals under-
went transthoracic echocardiography at the 4 h and 21 day,
and the method is described in detail in the following part. A
total of 30 animals were included into the study, and sur-
vival rate was recorded in treated group.
To identify the location and degradation of sprayed platelet
fibrin patch in vivo, we prelabeled the platelet fibrinogen
components by incubation with Texas Red-X succinimidyl
ester (1mg/mL [Invitrogen, Carlsbad, CA]) at 37C for 0.5 h.
Another cohorts of animals (n= 12) were induced MI and
sprayed with labeled platelet fibrin gel on the MI surface.
Following MI induction, one animal died due to bleeding, one
animal died of sudden cardiac arrest, and one animal died of
unknown reason. Thus, a total of nine animals were finally
included in the analysis, and each three were sacrificed at day
0, 4, and 7 for fluorescent image and histology.
Cardiac function assessment by echocardiography
Animals underwent transthoracic echocardiography under
1.5% isofluorane–oxygen mixture anesthesia in supine posi-
tion at the 4 h and 21 day. The procedure was performed by an
animal cardiologist blind to the experimental design using a
Philips CX30 ultrasound system couple with a L15 high-
frequency probe. M-mode standard two-dimensional left
parasternal long-axis echocardiographic examination was
conducted. Ejection fraction (% EF) and fractional short-
ening (% FS) were used as cardiac function indicators.
EF% was determined by left ventricular end-diastolic
volume (LVEDV) and left ventricular end-systolic volume
FIG. 3. Cardiomyocyte
biocompatibility with the
sprayed platelet fibrin patch.
(A) Schematic graphs show-
ing neonatal rat cardiomyo-
cytes (NRCMs) were
cultured on presprayed gel
(NRCMs on Spray) or
sprayed gel directly onto
preplated NRCM (Spray on
NRCMs) or cultured NRCMs
on standard tissue culture
plate (NRCMs on TCP) as
control; (B, C) Calcein
(live)/EthD (dead) staining
reveals a distinct morphology
and no significant difference
for viability of NRCMs
grown with platelet fibrin gel
compared with those grown
on TCP at day 1 and 7 in
culture (n= 3). Scale bar =
10mm. ‘‘NS’’ indicates
p > 0.05 when compared
to each other by one-way
analysis of variance followed
by post hoc Bonferroni
correction.
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(LVESV), and the formula for calculation is (LVEDV -
LVESV/LVEDV) · 100%. FS is determined by left ven-
tricular end-diastolic diameter (LVEDD) and left ventricular
end-systolic diameter (LVESD), and the formula for calcula-
tion is (LVEDD - LVESD/LVEDD)·100%.
Heart morphometry and assessment of fibrosis
After the echocardiography study at day 21, animals were
euthanized and hearts were harvested and frozen in OCT
compound. Specimens were sectioned at 10mm thickness from
the apex to the ligation level with 100mm intervals. Masson’s
trichrome staining was performed as described by the manu-
facturer’s instructions (HT15 Trichrome Staining [Masson]
Kit; Sigma-Aldrich). Images were acquired with a PathScan
Enabler IV slide scanner (Advanced Imaging Concepts, Prin-
ceton, NJ). From the Masson’s trichrome stained images,
morphometric parameters, including viable myocardium and
scar size were measured in each section with NIH ImageJ
software. The percentage of viable myocardium as a fraction of
the scar area (infarcted size) was quantified as described.11
Three selected sections were quantified for each animal.
Immunohistochemistry
For immunohistochemistry staining, heart cryosections
were fixed with 4% paraformaldehyde, permeabilized, and
blocked with Protein Block Solution (DAKO, Carpinteria,
CA) containing 0.1% saponin (Sigma, St. Louis, MO), and
then incubated with the following antibodies overnight at 4
C: rabbit anti-von Willebrand factor (vWF, 1:200; Abcam),
mouse anti-alpha-sarcomeric actin (1:200; Sigma). FITC- or
Texas-Red secondary antibodies (1:100) were obtained from
Abcam Company and used for the conjunction with these
primary antibodies. For assessment of cell apoptosis, heart
cryosections were incubated with TUNEL solution (Roche
Diagnostics GmbH, Mannheim, Germany) and counterstained
with DAPI (Life Technology, NY). Images were taken by an
FIG. 4. Characterization of
sprayed platelet fibrin patch on
post-MI hearts. (A) Schematic de-
sign of sprayed labeled platelet fi-
brin patch in a mouse model of MI.
Animals were euthanized at sub-
sequent time point and hearts were
harvested for fluorescent image and
sliced for histology; (B) Animals
were sacrificed at day 0, day 4, and
7, gross pictures showed a uniform
platelet fibrin patch labeled with
Texas Red-X epifluorescence ester
on the surface of the MI heart at
subsequent time points; (C) cryo-
section of the heart enabled ready
identification of the platelet fibrin
patch by Texas Red-X epi-
fluorescence at day 0. Scale bar=
200 mm; (D) Heart cryosections
were stained with 4¢, 6-diamidino-
2-phenylindole (DAPI) for nuclei,
and alpha-sarcomeric actin (alpha-
SA) for cardiomyocytes, (arrows)
indicating sprayed gel was infil-
trating into the myocardium since
day 4. Scale bar = 100mm; (E) To
calculate the percentage of degra-
dation over time, the sprayed gel
area at days 4 and 7 were measured
and then normalized to the day 0
sprayed gel area; (F) Quantitation
of cardiomyocytes integrated by
the sprayed patch at different time
points. MI, myocardial infarction.
150 TANG ET AL.
Olympus epifluorescence microscopy system. The images and
analysis were obtained from the peri-infarct area.
Statistical analysis
All data are presented as mean – standard deviation.
Comparisons between any two groups were performed with
two-tailed unpaired or paired Student’s t-test. Comparisons
among more than two groups were performed with one-way
analysis of variance followed by post hoc Bonferroni cor-
rection. p < 0.05 was considered statistically significant.
Results
Characterization of the sprayed platelet
fibrin patch in vitro
Figure 1 depicts a schematic of the spray device and the
overall design of animal studies. In brief, platelet-rich
plasma and calcium-containing media solution were packed
in double-lumen syringe and sprayed out by compressed
CO2. Immediately after the spray, in situ polymerization
occurred to form a stable patch (Fig. 2A) on the glass slide.
Hematoxylin–eosin staining (Fig. 2B) and scanning electron
microscopy (Fig. 2C) revealed a fibrous structure of the
sprayed platelet fibrin patch. Enzyme-linked immunosorbent
assay revealed that the platelet fibrin gel released regener-
ative growth factors such as VEGF, IGF-1, HGF, PDGF,
and TGF-b (Fig. 2D–H). To test whether the sprayed gel is
compatible with cardiomyocytes, NRCMs were cultured on
TCP or the sprayed platelet fibrin patch, and to evaluate if
the pressure from the spray operation would affect the via-
bility of NRCMs, we also sprayed platelet fibrin gel directly
onto NRCMs (Fig. 3A). NRCMs exhibited elongated cell
morphology in the sprayed platelet fibrin gel (Fig. 3B). Live/
Dead assay revealed that NRCMs cultured with platelet fi-
brin gel exhibited a similar cell viability compared with
those cultured on TCP at day 1 and 7 (Fig. 3C). In addition,
NRCMs continued to beat spontaneously within the platelet
fibrin gel (Supplementary Movies S1–S3; Supplementary
Data are available online at www.liebertpub.com/tec).
Characterization of sprayed platelet fibrin
patch on post-MI hearts
To identify the location and degradation of sprayed
platelet fibrin patch in vivo, we prelabeled platelet fibrin gel
with Texas Red-X succinimidyl ester (Invitrogen) to enable
histological detection.12,13 We then evaluated the sprayed
platelet fibrin patch in a mouse model of MI (Fig. 4A). The
spray resulted in a uniform platelet fibrin patch on the sur-
face of the heart (Fig. 4B, C), and degradation of the patch
was observed over the time (Fig. 4E). Cryosections of the
FIG. 5. Overall study design of functional study for platelet fibrin patch on post-MI heart. (A) Schematic design of
sprayed platelet fibrin patch on mice heart withMI, animals were sacrificed after 4 h and 21day echocardiography detection,
following harvested hearts and sliced into three sections as illustrated. (B) Survival rate was calculated in mice post-MI with
different treatment. (C) Body weight changes of CD1 mice were recorded at various time points in groups with different
treatment.
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hearts enabled ready identification of the platelet fibrin gel
by Texas Red-X epifluorescence (Fig. 4C, D). Sprayed gel
was infiltrating into the myocardium (Fig. 4D, F).
Sprayed platelet fibrin patch attenuates LV remodeling
and preserves cardiac function
A total of 30 animals were enrolled into the study for ex-
ploring thebeneficial effects of sprayed cardiac patch (Fig. 5A).
The survival rate was calculated by the record of survival an-
imals, and 21-day post-MI was set as humane endpoints
(Fig. 5B). In the MI alone group, two animals died of bleeding
at day 1 post-MI, and one animal died of sudden cardiac arrest
at day 2 post-MI. In animals treated with sprayed fibrin gel
group, two mice died of bleeding at day 1 post-MI. Also, in
animals treated with sprayed platelet fibrin gel group, only one
mouse died of bleeding at day 1 post-MI. All other animals
survived. Therefore, a total of 24 animals were finally included
in the analysis (cardiac function and histopathology), distrib-
uted as follows: 6 in the SHAMgroup, 6 in theMI alone group,
6 in the MI+Fibrin Spray group, and 6 in the MI+Platelet
Fibrin Spray group. Body weights of these survived animals
were also recorded at subsequent timepoints to evaluate the life
quality of mice after different treatments (Fig. 5C).
Masson’s trichrome staining showed simultaneous detection
of scar (blue) and healthy myocardial (red) tissues, and platelet
fibrin patch-treated hearts exhibited attenuated LV remodeling
and less abnormal heart morphology (Fig. 6A). Concomitantly,
quantitative morphometry reflected that platelet fibrin patch-
treated hearts exhibited smaller infarct size (Fig. 6B), smaller
LV cavities (Fig. 6C), thicker infarcted walls (Fig. 6D), and
more viable myocardium (Fig. 6E), indicating the ability of
platelet fibrin patch to attenuate adverse LV remodeling.
To evaluate the therapeutic benefits of plateletfibrin gel spray
treatment, we also explored its ability to preserve or improve
cardiac function in post-MI hearts. Both LVEF and LVFS at
FIG. 6. Sprayed platelet
fibrin patch attenuates LV
remodeling and preserves
cardiac function. (A) Re-
presentative Masson’s
trichrome-stained heart sec-
tions obtained from hearts
21 days after surgery. Scar
tissue and viable myocar-
dium are identified by blue
and red stains respectively;
(B–E) Quantitative analysis
of infarct size, LV cavity
area, infarct wall thickness,
and viable tissue percentages
from the Masson’s trichrome
images (n= 3 animals per
group); (F, G) Left ventric-
ular fraction shortening
(LVFS) and left ventricular
ejection fraction (LVEF)
were measured by echocar-
diography at baseline (4 h
post-MI) and 21 days after-
ward in SHAM, MI alone,
MI +Fibrin Spray, and MI +
Platelet Fibrin Spray groups
(n = 6 animals per group);
*p < 0.05 when compared
with the SHAM group;
#p < 0.05 when compared
with MI + Platelet Fibrin
Spray group; &p < 0.05
when compared with MI
Alone group; %p< 0.05
when compared with
MI +Fibrin Spray group. LV,
left ventricular.
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baseline (4h post-MI) showed a similar decrease in MI alone
group or MI+Fibrin/Platelet Fibrin SPRAY group when com-
pared with SHAM group, indicating a comparable degree of
initial injury. Over the next 3 weeks, both LVEF and LVFS
declined in the MI alone group or preserved in the MI+Fibrin
Spray group, but were improved in the MI+Platelet Fibrin
SPRAY group (Fig. 6F, G). These results suggested that the
sprayed platelet fibrin patch is sufficient to attenuate the loss of
cardiac function after experimental MI.
Sprayed fibrin patch promotes endogenous repair
and attenuates myocardial apoptosis
To investigate whether the sprayed platelet fibrin patch
could promote endogenous repair, we stained heart section for
alpha-sarcomeric actin (cardiomyocytes) or vWF (endothelial
cells) 3 weeks post-MI. More cardiomyocytes (Fig. 7A; red)
and endothelial cells (Fig. 7B; red) were detected residing in
the infarcted area in MI treated with sprayed platelet fibrin
patch compared with the MI alone group. Quantitative anal-
ysis also confirmed those findings (Fig. 7A, B bar graphs).
TUNEL staining and analysis confirmed fewer apoptotic nu-
clei in the spray-treated hearts than in nontreated hearts
(Fig. 7C; red nuclei), suggesting that the spray treatment could
inhibit cell apoptosis after MI.
Discussion
MI represents a major cause of death and generates sig-
nificant socioeconomic costs.14 After MI, adult mammalian
hearts only retain negligible potency for repair and regenera-
tion. In contrast, sustained cardiomyocyte death and scaring
following injury can eventually lead to heart failure.15
FIG. 7. Sprayed platelet fibrin patch promotes endogenous repair and attenuates tissue apoptosis. (A) Cardiomyocytes
stained with alpha sarcomeric actin (a-SA) (red) in the hearts 21 days after MI surgery. The numbers of a-SA positive
cardiomyocytes were quantified (n = 3 animals per group). (B) Endothelial cells stained with von Willebrand factor (vWF)
(red) in the hearts 21 days after MI surgery. The numbers of vWF-positive endothelial cells were quantified (n = 3 animals
per group). (C) Representative fluorescent micrographs showing the presence of TUNEL+ apoptotic cells (red) in the hearts
of MI alone and MI + Platelet Fibrin Spray groups. The numbers of apoptotic-positive cells were quantified (n = 3 animals
per group). Scale bars = 100 mm. *p < 0.05 when compared with the treated with ‘‘MI Alone.’’
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To date, approaches to cardiac tissue engineering range
from injectable hydrogel to construction of complex cardiac
constructs.16 Intramuscular injections have variable outcomes
due to low biomaterials retention at the site of injection.17
Implanting engineered cardiac patch represents a promising
strategy for cardiac tissue engineering.5,18,19 However, the
placement of such a patch on the heart usually requires open-
chest surgery and suturing in the heart. Such procedures are
traumatic and time consuming.
The present study reported a novel way to deliver a
cardiac patch onto the heart with a minimally invasive
way. Platelet-rich plasma and calcium-containing media
solution were packed separately and passed through a
double-lumen syringe until the two met at the nozzle tip
where compressed air was used to spray the mixture onto
the heart. The mixture then formed a stable platelet fibrin
gel by in situ polymerization. This spray method can be
applied to other types of biomaterials. We used platelet
fibrin gel as the model biomaterial in this study because it is
well known for its biocompatibility and has been widely
applied in regenerative medicine.17,20 Previous studies have
also demonstrated that fibrin glue could improve the survival
of injectable skeletal myoblasts, bone marrow cells, marrow-
derived cardiac stem cells, adipose-derived stem cells, and
human induced pluripotent stem cell-derived cardiomyocy-
tesin MI hearts.21–26 Furthermore, injection of fibrin alone
(without cells) could preserve cardiac function after MI and
prevent negative LV remodeling.27 Also, our previous report
has demonstrated the positive role of platelet fibrin gel in
cardiac repair after MI.13
In the present study, we first demonstrated that a stable
platelet fibrin gel patch can be formed by this spray method
(Fig. 2A). To better understand the beneficial effects ex-
erted by sprayed platelet fibrin gel, we demonstrated that
sprayed platelet fibrin gel is nontoxic to cardiomyocytes
(Fig. 3) and could stay on the heart but degrade over the
time (Fig. 4). The sprayed cardiac patch contained inter-
connected pores (Fig. 2B, C) and could release paracrine
factors like VEGF, IGF-1, HGF, PDGF, and TGF-b
(Fig. 2D–H), which have been shown to promote cardiac
repair.11,28 It has been well known that VEGF is proan-
giogenic and IGF-1 stimulates mitogenesis, promotes dif-
ferentiation, and inhibits apoptosis in the heart.29,30 HGF
promotes cell proliferation, motility, morphogenesis, and
angiogenesis and also provides tissue protection after in-
jury.31 Also, previous studies have demonstrated that fac-
tors such as VEGF, IGF-1, and HGF could contribute to
tissue repair through their proangiogenic and antiapoptotic
roles.32–34 More particularly, VEGF, IGF-1, and HGF could
regulate the therapeutic effects of stem cells on injured heart
by the aforementioned mechanisms.35,36 On the contrary, the
contribution of sprayed platelet fibrin patch to infarct repair is
likely even more important. In terms of endogenous cell re-
generation, neovascularization and antiapoptosis, such ac-
tions are consistent with the reduced scar fibrosis, attenuated
LV remodeling and improved cardiac function post-MI
(Fig. 6). Most likely, paracrine effects have been the most
plausible mechanism, by which platelet fibrin gel exerted its
beneficial effects, which has been broadly investigated.7,13
Once sprayed on top of the infarcted heart, the cardiac patch
secretes regenerative factors to promote angiomyocardio-
genesis and reduce apoptosis (Fig. 7).
Conclusion
In summary, the use of this spraying system allowed for
placement of cardiac patch without the need for surgeries and
sutures. Spray painting of biomaterials on the surface of the
heart provides an effective strategy for cardiac repair afterMI.
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